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Letter to the Editor 
Diagnostic Genetics
Chronic Myeloid Leukemia With Rare Variant b2a3 
(e13a3) BCR-ABL1 Fusion
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Departments of Laboratory Medicine1 and Internal Medicine2, Yonsei University College of Medicine, Seoul, Korea
Dear Editor,
CML is characterized by reciprocal t(9;22)(q34;q11) transloca-
tion, which generates the BCR/ABL1 protein; that protein plays 
a critical role in the pathogenesis of CML. CML patients com-
monly harbor BCR-ABL1 fusion transcripts of types b3a2 
(e14a2) or b2a2 (e13a2), while types e1a2 or e19a2 are less 
common. CML cases with b2a3-type fusion, in which the ABL1 
exon 3 (a3) rather than exon 2 (a2) is fused to BCR, are rare. To 
date, only eight CML cases with solely b2a3-type fusion have 
been reported [1-6]. Here, we report a CML case with this rare 
b2a3-type BCR-ABL1 fusion and review the literature.
A 57-yr-old man with marked leukocytosis was referred to a 
tertiary-care hospital and diagnosed as having CML in the 
chronic phase. Peripheral blood analysis showed a white blood 
cell (WBC) count of 384.7×109/L with 1% blasts, as well as a 
hemoglobin concentration of 7.3 g/dL, and a platelet count of 
424×109/L. The bone marrow aspirate revealed a hypercellular 
marrow with left-shifted myeloid series and an increased num-
ber of megakaryocytes, with the occasional dwarf form. G-
banded karyotyping of the bone marrow cells demonstrated 
t(9;22)(q34;q11.2) in all of the 17 metaphase cells analyzed. A 
BCR/ABL1 gene rearrangement test by using reverse transcrip-
tion PCR (RT-PCR) with home-brewed primers complementary 
to the ABL1 exon 2 (a2) failed to detect the BCR-ABL1 fusion 
transcript (reference sequence: BCR, NM_004327.3; ABL1, 
NM_005157.5). Negative results were also obtained with quan-
titative real-time RT-PCR analysis using the ipsogen BCR-ABL1 
Mbcr IS-MMR Kit (Qiagen, Hilden, Germany). However, multi-
plex RT-PCR using the HemaVision kit (DNA Technology, Aar-
hus, Denmark) showed an atypical band of approximately 220 
base pairs, suggesting the presence of the b2a3-type BCR-
ABL1 fusion transcript (Fig. 1A). Sanger sequencing of the RT-
PCR product revealed fusion between the BCR exon 13 (b2) 
and the ABL1 exon 3 (a3) (Fig. 1B). The patient was started on 
nilotinib, which has been continued to the present.
The clinical significance of b2a3-type fusion in CML has not 
been determined owing to its rarity. Therefore, we reviewed the 
literature for CML cases with this type of fusion in order to un-
derstand its clinical characteristics (Table 1). Cases with con-
comitant expression of another type of fusion transcript were 
eliminated to exclude the clinical effect of the other fusion tran-
script. All the eight patients underwent favorable clinical 
courses; none progressed to the transformed stages of acceler-
ated or blast phases during the follow-up period. Additionally, 
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b2a3-type fusion CML seems to be sensitive to tyrosine kinase 
inhibitor (TKI) therapy. All five cases using TKI achieved com-
plete cytogenetic or major molecular responses. In contrast, two 
cases that used interferon α (IFN-α) as initial treatment modality 
showed only partial hematologic responses.
ABL1 exon 2 (a2), which is missing in the b2a3-type fusion, 
codes part of an Src homology (SH) 3 domain, known as a neg-
ative regulator of ABL1 tyrosine kinase [7]. Deletions and muta-
tions of the SH3 domain can solely elevate tyrosine kinase activ-
ity [7, 8]. Therefore, it can be postulated that absence of the 
SH3 domain in the BCR/ABL1 fusion protein would result in ag-
gressive clinical outcomes. However, several reports have sug-
gested that the SH3 domain induces STAT5 expression, which 
in turn contributes to BCR/ABL1-dependent leukemogenesis in 
vivo [9]. In a murine model, BCR/ABL1 with SH3 deletion re-
tains the ability to induce CML but shows delayed disease onset 
and increased survival compared with b2a2 mice [10]. One 
possible explanation for the delayed disease onset and in-
creased survival of these mice is the effect of the SH3 deletion 
on adhesion, invasion, and homing [9]. These findings are con-
sistent with favorable clinical outcomes for b2a3-type CML pa-
tients, but further studies are needed to clarify the phenotypic 
characteristics of b2a3-type CML.
Rare fusion transcripts may escape detection when methods 
that are optimized to detect typical fusion transcripts are used. 
Initially, we failed to detect b2a3-type BCR/ABL1 transcripts using 
the home-brewed PCR kit, which is designed only for typical fu-
sion type CML. Since the b2a3-type fusion transcript lacks exon 2 




Diagnostic phase Karyotype Treatment
Status at last F/U 
(month)
Liu, et al. (2003) [1] M/59 254/9.6/180 CP Ph Hy Myelofibrosis (24)
Liu, et al. (2003) [1] NA NA CP Ph NA CP (96)
Liu, et al. (2003) [1] M/49 87/11.5/331 CP Ph IFN/Hy> Imatinib CCR (24)
Moravcova, et al. (2005) [2] M/42 27.8/14.3/233 CP Ph IFN>Imatinib CCR (29)
Pienkowska-Grela, et al. (2007) [3] M/39 163/NA/NA CP Complex with Ph† Hy> Imatinib CCR (22)
Masuko, et al. (2009) [4] M/37 8.67/11.5/2,016 CP Complex with Ph‡ Imatinib MMR (24)
Achkar, et al. (2010) [5] F/25 122/10.3/156 CP Complex with Ph§ Hy CP (NA)
McCarron, et al. (2015) [6] M/66 NA CP Ph Imatinib CCR (14)
Present case M/57 384.7/7.3/424 CP Ph Nilotinib NA (3)
*Values are presented in the International System of Units (WBC, ×109/L; Hb, g/dL; Platelet, ×109/L); †51,XY,+8,+8,+8,+8,t(9;22)(q34;q11.2),+der(22)
t(9;22)[6]/52,XY,idem,+der(22)x2[6]/46,XY,t(9;22)(q34;q11.2); ‡46,XX,der(9) (9pter →9q13: :9q34→9qter),der(22) (22pter→22q11: :9q34: :9q34: 
:9q13→9pter); §48,XX,+8,+der(12)t(12;19)(p11.2;q13.3),t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[8]/47,XX,+8,t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)
[2]/47,XX,+der(12)t(12;19)(p11.2;q13.3),t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[2]/46,XX,t(9;12;19;22)(q34.1;p11.2;q13.3;q11.2)[8].
Abbreviations: CBC, complete blood count; WBC, white blood cell; F/U, follow-up; CP, chronic phase; Ph, t(9;22)(q34;q11); Hy, hydroxyurea; IFN, interferon; 
NA, not available; CCR, complete cytogenetic response; MMR, major molecular response.
Fig. 1. (A) Agarose gel electrophoresis of multiplex reverse tran-
scription (RT)-PCR product showing an atypical band of approxi-
mately 220 base pairs, suggesting the presence of the b2a3-type 
BCR-ABL1 fusion transcript. Lane M, bp markers; Lane Pat, report-
ed patient with variant b2a3-type fusion transcript; Lane B, blank; 
Lane b2a2, positive control with b2a2 fusion transcript. (B) cDNA 
sequence results of the RT-PCR product demonstrating the b2a3-
type fusion transcript (reference sequence: BCR, NM_004327.3; 
ABL1, NM_005157.5). 
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of the ABL1 gene, PCR using primers that bind to sequences in 
the ABL1 exon 2 may fail to amplify target fusion transcripts.
We report a case of CML with the b2a3-type BCR/ABL1 fu-
sion transcript. The literature review shows that the majority of 
b2a3-type CML cases have a benign prognosis and good sensi-
tivity to TKI therapy. Clinical laboratories should be aware that 
rare fusion transcripts such as b2a3 may not be detected when 
using primers complementary to ABL1 exon 2.
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